Alvotech Cash Flow Statement
NASDAQ: ALVOHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
5.78+0.11 (+1.94%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Alvotech free cash flow
In fiscal 2025, Alvotech generated -$50.2 million of operating cash flow and spent $64.5 million on capital expenditures. That left free cash flow of -$114.7 million, a free-cash-flow margin of -19.6% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Alvotech cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 |
|---|---|---|---|---|---|---|
| Net Income | 27.92M | -231.86M | -551.73M | -513.58M | -101.50M | -170.04M |
| Net Income growth (YoY) | — | — | — | — | — | — |
| Depreciation & Amortization | 37.85M | 31.30M | 24.21M | 20.41M | 18.20M | 16.42M |
| Stock-Based Compensation | 7.38M | 7.63M | 18.03M | 10.32M | 0 | — |
| Operating Cash Flow | -50.20M | -236.84M | -312.19M | -312.39M | -228.17M | -74.30M |
| Capital Expenditures | -64.47M | -53.66M | -33.23M | -37.88M | -20.46M | -7.49M |
| Investing Cash Flow | -104.22M | -18.87M | -46.34M | -63.54M | -40.63M | -16.90M |
| Debt Issued | 233.48M | 896.26M | 278.83M | 193.68M | 113.82M | 30.00M |
| Debt Repaid | -25.42M | -749.08M | -99.37M | -34.71M | -37.50M | -2.90M |
| Financing Cash Flow | 270.83M | 297.31M | 301.32M | 424.91M | 254.83M | 55.40M |
| Free Cash Flow | -114.67M | -290.50M | -345.42M | -350.27M | -248.63M | -81.78M |
This table shows 6 annual periods of Alvotech's cash flow statement, from FY 2025 back to FY 2020, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow ALVO's reporting calendar. What is a cash flow statement?